Table 3.
Reported lipid and renal outcomes in PWH receiving DTG + 3TC
| Study | PWH on DTG + 3TC, N | Time point (week)a | Lipid outcomes with DTG + 3TC vs. BL | Renal outcomes with DTG + 3TC vs. BL | |
|---|---|---|---|---|---|
| Maggiolo (2017) [69] | 94 | 24 |
Significant decrease in TC (− 7 mg/dl; P = 0.047) and TG (− 31 mg/dl; P = 0.012) Significant increase in HDL (+ 4 mg/dl; P = 0.036) No significant change in LDL (− 7 mg/dl; P = 0.355) |
Improved | Significant increase in mean creatinine level was observed in the first 8 weeks (0.06 mg/dl; P < 0.0001) and leveled out at 24 week |
| Hidalgo-Tenorio (2019) [52] | 177 | 48 |
Significant decrease in TC (− 8 mg/dl; P = 0.002), TG (− 48 mg/dl; P = 0.0001), and HDL (− 25 mg/dl; P = 0.002) Significant increase in LDL (+ 14 mg/dl; P = 0.003) and TC:HDL ratio (P = 0.0018) |
Improved | Significant increase in mean creatinine level from baseline (1.04 mg/dl) to Week 48 (1.15 mg/dl; P = 0.001) but changes were not considered clinically relevant |
| Reynes (2016) [70] | 27 | 48 | NR | – | Median decrease from baseline of − 2.5 and − 9 ml/min/1.73 m2 for PWH switching from a previous regimen with or without TDF, respectively |
| Yagci-Caglayik (2017) [34] | 32 | 30 | No statistically significant change in lipids | Unchanged |
eGFR increased to > 60 ml/min/m2 in 3 of 13 PWH with BL eGFR < 60 ml/min/m2 Creatinine increased in 1 individual |
| Baldin (2019) [30] | 556 | 144 |
Significant decrease in TC (− 9.1 mg/dl; P = 0.007) and TG (− 2.7 mg/dl; P = 0.009) Significant increase in HDL (+ 5.4 mg/dl; P = 0.036) |
Improved | NR |
| Tan (2019) [36] | 56 | 112 | No significant change in unfasted TC levels | Unchanged | Small decrease in median eGFR from baseline (− 1 ml/min/1.73 m2) |
| Hiryak (2020) [42] | 49 | 16 | NR | – | No change in median serum creatinine (− 0.06 mg/dl (IQR, − 0.15, 0.06) |
Duplicate studies have been removed
BL baseline, DTG dolutegravir, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, NR not reported, PWH people with HIV, TC total cholesterol, TG triglycerides, 3TC lamivudine
aValue in this column refers to the time point at which the outcome was reported or median follow-up/length of treatment if no specific time point was provided by the authors